For instance, a clinical trial study by Wu et al. [48] reported that the combination of alpelisib with pembrolizumab (anti-PD-1) improved responses in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutant breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.